Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors

Qiuji Wu; Qian Chu; Hongyan Zhang; Bin Yang; Xudong He; Yahua Zhong; Xianglin Yuan; Melvin L K Chua; Conghua Xie

doi:10.1002/cac2.12077

Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors

Cancer Commun (Lond). 2020 Aug;40(8):374-379. doi: 10.1002/cac2.12077. Epub 2020 Jul 15.

Authors

Qiuji Wu^{1

2

3}, Qian Chu⁴, Hongyan Zhang^{1

2

3}, Bin Yang⁵, Xudong He⁶, Yahua Zhong^{1

2

3}, Xianglin Yuan⁴, Melvin L K Chua^{1

7

8}, Conghua Xie^{1

2

3}

Affiliations

¹ Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, P. R. China.
² Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, P. R. China.
³ Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, P. R. China.
⁴ Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, P. R. China.
⁵ Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430079, P. R. China.
⁶ Department of Gastroenterology, Dongfeng Hospital, Hubei University of Medicine, Shiyan, Hubei, 442000, P. R. China.
⁷ Divisions of Radiation Oncology and Medical Sciences, National Cancer Centre Singapore, Singapore, 169610, Singapore.
⁸ Oncology Academic Programme, Duke-NUS Medical School, Singapore, 169857, Singapore.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Betacoronavirus / pathogenicity*
COVID-19
Coronavirus Infections / complications
Coronavirus Infections / drug therapy*
Coronavirus Infections / immunology
Coronavirus Infections / virology
Humans
Immunotherapy / adverse effects*
Neoplasms / complications
Neoplasms / drug therapy*
Neoplasms / immunology
Neoplasms / virology
Pandemics
Pneumonia, Viral / complications
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / immunology
Pneumonia, Viral / virology
SARS-CoV-2
Treatment Outcome

Publication types

MeSH terms

Grants and funding